Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.17USD
4:00pm EDT
Change (% chg)

$0.52 (+7.82%)
Prev Close
$6.65
Open
$6.72
Day's High
$7.22
Day's Low
$6.72
Volume
216,063
Avg. Vol
166,652
52-wk High
$15.01
52-wk Low
$4.10

Select another date:

Tue, May 15 2018

BRIEF-Insys Therapeutics Responds To Unsealing Of Previously Filed Qui Tam Complaints

* INSYS THERAPEUTICS RESPONDS TO UNSEALING OF PREVIOUSLY FILED QUI TAM COMPLAINTS AND RECAPS TRANSFORMATION EFFORTS

U.S. joins whistleblower case against Insys over kickbacks

The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications.

U.S. joins lawsuits against opioid maker Insys over kickback scheme

May 14 The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit.

BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East

* INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST

BRIEF-Insys Therapeutics Reports First Quarter 2018 Results

* Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S

Ex-Insys employee in U.S. opioid case sentenced to home confinement

A former Insys Therapeutics Inc sales representative was sentenced on Monday to six months of home confinement after admitting that she participated in a scheme to pay kickbacks to two Alabama doctors to prescribe a fentanyl-based medication.

Ex-Insys employee in U.S. opioid case sentenced to home confinement

April 23 A former Insys Therapeutics Inc sales representative was sentenced on Monday to six months of home confinement after admitting that she participated in a scheme to pay kickbacks to two Alabama doctors to prescribe a fentanyl-based medication.

BRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated Device

* INSYS THERAPEUTICS TO ADVANCE CLINICAL RESEARCH OF DRONABINOL INHALATION USING NOVEL BREATH-ACTUATED DEVICE

Insys blasts 'incredibly broad' Maryland opioid probe subpoena

Insys Therapeutics Inc is blasting as "incredibly broad" a subpoena issued by Maryland's attorney general requiring the opioid manufacturer to search virtually all employees' emails created before December 2016.

BRIEF-Insys Therapeutics Appoints Trudy Vanhove To Board Of Directors

* INSYS THERAPEUTICS APPOINTS TRUDY VANHOVE TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Select another date: